1. In Vivo
  2. >>Innovation

Applying Scientific Rigor To Microbiome Therapeutics

PharmaBiome’s Second-Generation Candidates

 
• By John Davis

Tomas de Wouters, one of In Vivo’s 2020 Rising Leaders, has taken on the complex challenge of the microbiome, aiming to design the next generation of microbiome therapeutic candidates targeted at host-microbial interactions. 

Microbiome_Analysis
• Source: Shutterstock

Translating a better understanding of the microbiome, the large mass of micro-organisms that we all carry around in our gastrointestinal (GI) tract, our skin and elsewhere, into beneficial therapeutic products is proving to be a long and painstaking process. Still, it is one that may be attractive to researchers with a background in complex systems and processes.

That is according to Tomas de Wouters, co-founder and CEO of the five-year-old Swiss start-up, PharmaBiome, and one of In...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

 
• By David Wild

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

BioBytes: AI-Related Deals In Q2 ‘25

 
• By David Wild

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

More from In Vivo

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Deals Shaping The Industry, June 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.